QuantumScape rallies on Cobra-based B1 shipment milestone, new OEM engagement, and extended cash runway through 2030.
| Metric |
Actual |
Consensus |
Beat/Miss |
| GAAP EPS |
–$0.18 |
–$0.20 |
✅ Beat |
| Adjusted EBITDA |
–$61.4M |
–$65M est. |
✅ Beat |
| Revenue / Billings |
$12.8M (customer billings) |
$10M modeled |
✅ Beat |
QuantumScape delivered a constructive print — narrowing losses, achieving a critical commercialization milestone with first shipments of Cobra-based QSE-5 B1 cells, and introducing a new metric (“customer billings”) that points to genuine commercial traction. The 10% stock surge reflects investor enthusiasm over both execution and credibility in the transition from R&D to early monetization.